ArticleActa pharmaceutica Sinica. B2022
Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma.
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- A destination-driven framework for nanoparticle-enabled targeted protein degradation.Acta pharmaceutica Sinica. B · 2026Review
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.ACS materials letters · 2026Article
- Shooting two hawks with one arrow: manganese-doped mesoporous carriers coordinate STING activation and enhanced mRNA translation forMaterials today. Bio · 2026Article
- A photothermal immune hydrogel dressing for enhanced post-melanoma resection treatment.Journal of nanobiotechnology · 2026Article
- MircoRNAs as regulators of regulated cell death in cancer progression: a focus on ferroptosis, anoikis and pyroptosis.Frontiers in pharmacology · 2026Review
- The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine.Science advances · 2025Review
- The Forgotten Innate Immune Cells: Unraveling Their Prospective Interactions with Nanomaterials.International journal of nanomedicine · 2025Review
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- Recent advances in the bench-to-bedside translation of cancer nanomedicines.Acta pharmaceutica Sinica. B · 2025Review
- Nanotechnology as a Promising Method in the Treatment of Skin Cancer.International journal of molecular sciences · 2024Review
- Advancements and Challenges in the Application of Metal-Organic Framework (MOF) Nanocomposites for Tumor Diagnosis and Treatment.International journal of nanomedicine · 2024Review
- Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems.International journal of nanomedicine · 2024Review
- Dual-Modal Near-Infrared Organic Nanoparticles: Integrating Mild Hyperthermia Phototherapy with Fluorescence Imaging.International journal of nanomedicine · 2024Article
- Enhancing radiotherapy for melanoma: the promise of high-Z metal nanoparticles in radiosensitization.Nanomedicine (London, England) · 2024Review
- Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases.Drug delivery · 2023Review
- Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies.Acta pharmaceutica Sinica. B · 2023Review
- Advancements in nanoparticle-based treatment approaches for skin cancer therapy.Molecular cancer · 2023Review
- Comprehensive study upon physicochemical properties of bio-ZnO NCs.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photothermal therapy has been intensively investigated for treating cancer in recent years. However, the long-term therapeutic outcome remains unsatisfying due to the frequently occurred metastasis and recurrence. To address this challenge, immunotherapy has been combined with photothermal therapy to activate anti-tumor immunity and relieve the immunosuppressive microenvironment within tumor sites. Here, we engineered silica-based core‒shell nanoparticles (JQ-1@PSNs-R), in which silica cores were coated with the photothermal agent polydopamine, and a bromodomain-containing protein 4 (BRD4) inhibitor JQ-1 was loaded in the polydopamine layer to combine photothermal and immune therapy for tumor elimination. Importantly, to improve the therapeutic effect, we increased the surface roughness of the nanoparticles by hydrofluoric acid (HF) etching during the fabrication process, and found that the internalization of JQ-1@PSNs-R was significantly improved, leading to a strengthened photothermal killing effect as well as the increased intracellular delivery of JQ-1. In the animal studies, the multifunctional nanoparticles with rough surfaces effectively eradicated melanoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.